Suppression of T cells by myeloid-derived suppressor cells in cancer

详细信息    查看全文

• 作者：Jieying Chen^a ; Yingnan Ye^a ; Pengpeng Liu^b ; Wenwen Yu^a ; Feng Wei^a ; Hui Li^a ; Jinpu Yu^a ; ^b ; ^{yu_jinpu@sina.com}
• 关键词：Myeloid-derived suppressor cell ; Immune suppression ; T cell ; Targeted therapy ; Cancer
• 刊名：Human Immunology
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：78
• 期：2
• 页码：113-119
• 全文大小：774 K
• 卷排序：78

文摘

Myeloid-derived suppressor cells (MDSCs) are a population of immature myeloid cells defined by their immunosuppression. Elevated levels of certain soluble cytokines in tumor microenvironment, such as IL-6 and IL-10, contribute to the recruitment and accumulation of tumor-associated MDSCs. In turn, MDSCs secret IL-6 and IL-10 and form a positive self-feedback to promote self-expansion. MDSCs also release other soluble cytokines such as TGF-β and chemokines to exert their suppressive function by induction of regulatory T cells. Exhaustion of some amino acids by MDSCs with many secretory enzymes or membrane transporters as well as their metabolites leads to blockage of T cells development. The interaction of membrane molecules on MDSCs and T cells leads inactivation and apoptosis of T cells. There may be one or some dominant mechanism(s) by which MDSCs impair the immune system in different tumor microenvironment. Thus, it is important to identify the subpopulations of MDSCs and clarify the dominant mechanism(s) through which MDSCs inhibit antitumor immunity in order to establish a more individual immunotherapy by eliminating MDSCs-mediated suppression. Currently studies concentrated on therapeutic strategies targeting MDSCs have obtained promising results. However, more studies are needed to demonstrate their clinical safety and efficacy.